Experienced in Autoimmune Hemolytic Anemia

Opass Putcharoen

Bangkok, TH 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Autoimmune Hemolytic Anemia
Bangkok, TH 
OverviewLocationsClinical Research

Overview

Opass Putcharoen practices in Bangkok, Thailand. Putcharoen is rated as an Experienced expert by MediFind in the treatment of Autoimmune Hemolytic Anemia. Their top areas of expertise are HIV/AIDS, Severe Acute Respiratory Syndrome (SARS), Pulmonary Actinomycosis, COVID-19, and Kidney Transplant.

Their clinical research consists of co-authoring 60 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Autoimmune Hemolytic Anemia.

Locations

Bangkok, Thailand
Other Locations
Thailand

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Efficacy, Safety and Pharmacokinetics of Dolutegravir 50 Mg Once Daily with Food Versus Dolutegravir 50 Mg Twice Daily in HIV/TB Co-infected Patients Receiving Rifampin-based Antituberculosis Therapy
Efficacy, Safety and Pharmacokinetics of Dolutegravir 50 Mg Once Daily with Food Versus Dolutegravir 50 Mg Twice Daily in HIV/TB Co-infected Patients Receiving Rifampin-based Antituberculosis Therapy
Enrollment Status: Recruiting
Publish Date: October 02, 2024
Intervention Type: Drug
Study Drug: Dolutegravir
Study Phase: Phase 2
A Pilot Study of the Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly With Lopinavir/Ritonavir Based HAART in HIV/TB Co-infected Patients
A Pilot Study of the Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly With Lopinavir/Ritonavir Based HAART in HIV/TB Co-infected Patients
Enrollment Status: Completed
Publish Date: February 12, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

59 Total Publications

A combined prospective and retrospective comparative study evaluating renal outcomes after switching from TDF + FTC + EFV to TDF/3TC/DTG (TLD) vs. DTG + 3TC in virologically suppressed Thai people with HIV.
A combined prospective and retrospective comparative study evaluating renal outcomes after switching from TDF + FTC + EFV to TDF/3TC/DTG (TLD) vs. DTG + 3TC in virologically suppressed Thai people with HIV.
Journal: HIV research & clinical practice
Published: May 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Putcharoen's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile